Page 5 - Vitro Diagnostics News Today

/PRNewswire/ -- The medical device manufacturing outsourcing market is expected to grow by USD 46.24 billion from 2022 to 2027. In addition, the momentum of...

The European Commission proposed Tuesday to improve the availability of in vitro diagnostics and extend the time for companies to apply the In Vitro Diagnostics regulation.

Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The

BioCardia (NASDAQ:BCDA – Get Free Report) and Vitro Diagnostics (OTCMKTS:VODG – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership. Earnings and Valuation This table compares BioCardia and Vitro […]

Venus Concept (NASDAQ:VERO – Get Free Report) and Surmodics (NASDAQ:SRDX – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations. Institutional and Insider Ownership 87.4% of Venus Concept […]

/PRNewswire/ -- The pharmaceutical contract manufacturing market is expected to grow by USD 58 billion from 2022 to 2027. In addition, the momentum of the...

Venus Concept (NASDAQ:VERO – Get Free Report) and Surmodics (NASDAQ:SRDX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends. Earnings and Valuation This table compares Venus Concept […]

Join us for the WHO's Week of Quality for IVDs training program. Register your interest to participate in this valuable training program. IVD manufacturers and regulatory authorities (Ministry of Health, National Regulatory Authorities) in all WHO regions are welcome to attend.

Sidoti reiterated their neutral rating on shares of Surmodics (NASDAQ:SRDX – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. The brokerage currently has a $43.00 target price on the stock. SRDX has been the topic of a number of other reports. Needham & Company LLC reaffirmed a hold rating on […]

Lake Street Capital reissued their hold rating on shares of Surmodics (NASDAQ:SRDX – Free Report) in a research report report published on Wednesday, Marketbeat reports. Lake Street Capital currently has a $43.00 target price on the stock. SRDX has been the subject of a number of other research reports. StockNews.com cut Surmodics from a strong-buy […]